The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers

Sophie Leboulleux, Pamela Rose Schroeder, Martin Schlumberger, Paul W Ladenson

Research output: Contribution to journalArticle

Abstract

This article provides an update on the use of 2-[18F]-fluoro-2- deoxyglucose PET in the follow-up of patients treated for differentiated thyroid carcinoma (DTC). Although DTC recurrence is principally identified by a detectable basal or TSH-stimulated thyroglobulin level, PET helps to localize recurrent disease in patients with normal 131I total-body scans and other normal anatomic imaging studies. The sensitivity of PET for localization of recurrence ranges from 45% to 100% according to tumor burden and differentiation. Whether PET should be performed after TSH stimulation is unclear, but several studies have reported an increase in the number of lesions detected by uptake of 2-[18F]-fluoro-2-deoxyglucose in this setting. Dependent on a center's approach, PET can alter therapeutic management in 9-51% of cases. Furthermore, PET might have a prognostic impact on survival in patients with metastatic disease and aid clinicians in selecting patients who need closer follow-up or aggressive treatment. PET can, therefore, be used advantageously in the follow-up of patients with DTC and can localize disease in patients with elevated thyroglobulin levels, normal total-body scans, and normal findings on conventional imaging modalities. In patients in whom local treatment is planned, especially those with aggressive pathologic variants of thyroid cancer, PET can exclude distant metastases. In patients with metastatic disease, PET can help to identify patients needing closer follow-up.

Original languageEnglish (US)
Pages (from-to)112-121
Number of pages10
JournalNature Clinical Practice Endocrinology and Metabolism
Volume3
Issue number2
DOIs
StatePublished - Feb 2007

Fingerprint

Thyroid Neoplasms
Thyroglobulin
Fluorodeoxyglucose F18
Recurrence
Tumor Burden
Therapeutics
Neoplasm Metastasis
Survival

Keywords

  • Epithelial
  • Fluorodeoxyglucose
  • PET
  • Thyroid cancer

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. / Leboulleux, Sophie; Schroeder, Pamela Rose; Schlumberger, Martin; Ladenson, Paul W.

In: Nature Clinical Practice Endocrinology and Metabolism, Vol. 3, No. 2, 02.2007, p. 112-121.

Research output: Contribution to journalArticle

@article{95e1b9ba2e194741a73e31ca6f8b7ec7,
title = "The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers",
abstract = "This article provides an update on the use of 2-[18F]-fluoro-2- deoxyglucose PET in the follow-up of patients treated for differentiated thyroid carcinoma (DTC). Although DTC recurrence is principally identified by a detectable basal or TSH-stimulated thyroglobulin level, PET helps to localize recurrent disease in patients with normal 131I total-body scans and other normal anatomic imaging studies. The sensitivity of PET for localization of recurrence ranges from 45{\%} to 100{\%} according to tumor burden and differentiation. Whether PET should be performed after TSH stimulation is unclear, but several studies have reported an increase in the number of lesions detected by uptake of 2-[18F]-fluoro-2-deoxyglucose in this setting. Dependent on a center's approach, PET can alter therapeutic management in 9-51{\%} of cases. Furthermore, PET might have a prognostic impact on survival in patients with metastatic disease and aid clinicians in selecting patients who need closer follow-up or aggressive treatment. PET can, therefore, be used advantageously in the follow-up of patients with DTC and can localize disease in patients with elevated thyroglobulin levels, normal total-body scans, and normal findings on conventional imaging modalities. In patients in whom local treatment is planned, especially those with aggressive pathologic variants of thyroid cancer, PET can exclude distant metastases. In patients with metastatic disease, PET can help to identify patients needing closer follow-up.",
keywords = "Epithelial, Fluorodeoxyglucose, PET, Thyroid cancer",
author = "Sophie Leboulleux and Schroeder, {Pamela Rose} and Martin Schlumberger and Ladenson, {Paul W}",
year = "2007",
month = "2",
doi = "10.1038/ncpendmet0402",
language = "English (US)",
volume = "3",
pages = "112--121",
journal = "Nature Reviews Endocrinology",
issn = "1759-5029",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers

AU - Leboulleux, Sophie

AU - Schroeder, Pamela Rose

AU - Schlumberger, Martin

AU - Ladenson, Paul W

PY - 2007/2

Y1 - 2007/2

N2 - This article provides an update on the use of 2-[18F]-fluoro-2- deoxyglucose PET in the follow-up of patients treated for differentiated thyroid carcinoma (DTC). Although DTC recurrence is principally identified by a detectable basal or TSH-stimulated thyroglobulin level, PET helps to localize recurrent disease in patients with normal 131I total-body scans and other normal anatomic imaging studies. The sensitivity of PET for localization of recurrence ranges from 45% to 100% according to tumor burden and differentiation. Whether PET should be performed after TSH stimulation is unclear, but several studies have reported an increase in the number of lesions detected by uptake of 2-[18F]-fluoro-2-deoxyglucose in this setting. Dependent on a center's approach, PET can alter therapeutic management in 9-51% of cases. Furthermore, PET might have a prognostic impact on survival in patients with metastatic disease and aid clinicians in selecting patients who need closer follow-up or aggressive treatment. PET can, therefore, be used advantageously in the follow-up of patients with DTC and can localize disease in patients with elevated thyroglobulin levels, normal total-body scans, and normal findings on conventional imaging modalities. In patients in whom local treatment is planned, especially those with aggressive pathologic variants of thyroid cancer, PET can exclude distant metastases. In patients with metastatic disease, PET can help to identify patients needing closer follow-up.

AB - This article provides an update on the use of 2-[18F]-fluoro-2- deoxyglucose PET in the follow-up of patients treated for differentiated thyroid carcinoma (DTC). Although DTC recurrence is principally identified by a detectable basal or TSH-stimulated thyroglobulin level, PET helps to localize recurrent disease in patients with normal 131I total-body scans and other normal anatomic imaging studies. The sensitivity of PET for localization of recurrence ranges from 45% to 100% according to tumor burden and differentiation. Whether PET should be performed after TSH stimulation is unclear, but several studies have reported an increase in the number of lesions detected by uptake of 2-[18F]-fluoro-2-deoxyglucose in this setting. Dependent on a center's approach, PET can alter therapeutic management in 9-51% of cases. Furthermore, PET might have a prognostic impact on survival in patients with metastatic disease and aid clinicians in selecting patients who need closer follow-up or aggressive treatment. PET can, therefore, be used advantageously in the follow-up of patients with DTC and can localize disease in patients with elevated thyroglobulin levels, normal total-body scans, and normal findings on conventional imaging modalities. In patients in whom local treatment is planned, especially those with aggressive pathologic variants of thyroid cancer, PET can exclude distant metastases. In patients with metastatic disease, PET can help to identify patients needing closer follow-up.

KW - Epithelial

KW - Fluorodeoxyglucose

KW - PET

KW - Thyroid cancer

UR - http://www.scopus.com/inward/record.url?scp=33846437453&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33846437453&partnerID=8YFLogxK

U2 - 10.1038/ncpendmet0402

DO - 10.1038/ncpendmet0402

M3 - Article

C2 - 17237838

AN - SCOPUS:33846437453

VL - 3

SP - 112

EP - 121

JO - Nature Reviews Endocrinology

JF - Nature Reviews Endocrinology

SN - 1759-5029

IS - 2

ER -